These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 20140939)

  • 1. Methylthioadenosine phosphorylase and activated insulin-like growth factor-1 receptor/insulin receptor: potential therapeutic targets in chordoma.
    Sommer J; Itani DM; Homlar KC; Keedy VL; Halpern JL; Holt GE; Schwartz HS; Coffin CM; Kelley MJ; Cates JM
    J Pathol; 2010 Apr; 220(5):608-17. PubMed ID: 20140939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target.
    Shalaby A; Presneau N; Ye H; Halai D; Berisha F; Idowu B; Leithner A; Liegl B; Briggs TR; Bacsi K; Kindblom LG; Athanasou N; Amary MF; Hogendoorn PC; Tirabosco R; Flanagan AM
    J Pathol; 2011 Feb; 223(3):336-46. PubMed ID: 21171079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of methylthioadenosine phosphorylase cDNA in p16-, MTAP- malignant cells: restoration of methylthioadenosine phosphorylase-dependent salvage pathways and alterations of sensitivity to inhibitors of purine de novo synthesis.
    Chen ZH; Olopade OI; Savarese TM
    Mol Pharmacol; 1997 Nov; 52(5):903-11. PubMed ID: 9351982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of methylthioadenosine phosphorylase (MTAP) protein expression with MTAP and CDKN2A copy number in malignant pleural mesothelioma.
    Chapel DB; Dubuc AM; Hornick JL; Sholl LM
    Histopathology; 2021 Jun; 78(7):1032-1042. PubMed ID: 33387364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The transcriptional factors CDX2 and FOXA1 in chordomas.
    Dridi M; Boutonnat J; Dumollard JM; Peoc'h M; Karpathiou G
    Pathol Res Pract; 2020 Nov; 216(11):153160. PubMed ID: 32911347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine kinase receptor expression in chordomas: phosphorylated AKT correlates inversely with outcome.
    de Castro CV; Guimaraes G; Aguiar S; Lopes A; Baiocchi G; da Cunha IW; Campos AH; Soares FA; Begnami MD
    Hum Pathol; 2013 Sep; 44(9):1747-55. PubMed ID: 23618355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MTAP is an independent prognosis marker and the concordant loss of MTAP and p16 expression predicts short survival in non-small cell lung cancer patients.
    Su CY; Chang YC; Chan YC; Lin TC; Huang MS; Yang CJ; Hsiao M
    Eur J Surg Oncol; 2014 Sep; 40(9):1143-50. PubMed ID: 24969958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma.
    García-Castellano JM; Villanueva A; Healey JH; Sowers R; Cordon-Cardo C; Huvos A; Bertino JR; Meyers P; Gorlick R
    Clin Cancer Res; 2002 Mar; 8(3):782-7. PubMed ID: 11895909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent alterations in p16/CDKN2A identified by immunohistochemistry and FISH in chordoma.
    Cottone L; Eden N; Usher I; Lombard P; Ye H; Ligammari L; Lindsay D; Brandner S; Pižem J; Pillay N; Tirabosco R; Amary F; Flanagan AM
    J Pathol Clin Res; 2020 Apr; 6(2):113-123. PubMed ID: 31916407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does insulin-like growth factor 1 receptor (IGF-1R) targeting provide new treatment options for chordomas? A retrospective clinical and immunohistochemical study.
    Scheipl S; Froehlich EV; Leithner A; Beham A; Quehenberger F; Mokry M; Stammberger H; Varga PP; Lazáry A; Windhager R; Gattenloehner S; Liegl B
    Histopathology; 2012 May; 60(6):999-1003. PubMed ID: 22372631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.
    Berg KB; Dacic S; Miller C; Cheung S; Churg A
    Arch Pathol Lab Med; 2018 Dec; 142(12):1549-1553. PubMed ID: 30059257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical analysis of receptor tyrosine kinase signal transduction activity in chordoma.
    Fasig JH; Dupont WD; LaFleur BJ; Olson SJ; Cates JM
    Neuropathol Appl Neurobiol; 2008 Feb; 34(1):95-104. PubMed ID: 17973908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concordant loss of MTAP and p16/CDKN2A expression in gastroesophageal carcinogenesis: evidence of homozygous deletion in esophageal noninvasive precursor lesions and therapeutic implications.
    Powell EL; Leoni LM; Canto MI; Forastiere AA; Iocobuzio-Donahue CA; Wang JS; Maitra A; Montgomery E
    Am J Surg Pathol; 2005 Nov; 29(11):1497-504. PubMed ID: 16224217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of E-cadherin in chordomas: diagnostic marker and possible role of tumor cell affinity.
    Mori K; Chano T; Kushima R; Hukuda S; Okabe H
    Virchows Arch; 2002 Feb; 440(2):123-127. PubMed ID: 11964040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of MTAP expression is a negative prognostic marker in Ewing sarcoma family of tumors.
    Abrahao-Machado LF; Antunes B; Filippi RZ; Volc S; Boldrini E; Menezes WP; Reis RM; de Camargo OP
    Biomark Med; 2018 Jan; 12(1):35-44. PubMed ID: 29243509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brachyury, SOX-9, and podoplanin, new markers in the skull base chordoma vs chondrosarcoma differential: a tissue microarray-based comparative analysis.
    Oakley GJ; Fuhrer K; Seethala RR
    Mod Pathol; 2008 Dec; 21(12):1461-9. PubMed ID: 18820665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of vascular endothelial growth factor receptor 2 (VEGFR-2), inducible nitric oxide synthase (iNOS), and Ki-M1P in skull base chordoma: a series of 145 tumors.
    Akhavan-Sigari R; Gaab MR; Rohde V; Brandis A; Tezval H; Abili M; von Eckardstein K; Ostertag H
    Neurosurg Rev; 2014 Jan; 37(1):79-88. PubMed ID: 23999886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of c-met proto-oncogene product (c-MET) in benign and malignant bone tumors.
    Naka T; Iwamoto Y; Shinohara N; Ushijima M; Chuman H; Tsuneyoshi M
    Mod Pathol; 1997 Aug; 10(8):832-8. PubMed ID: 9267827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens.
    Berg KB; Churg AM; Cheung S; Dacic S
    Cancer Cytopathol; 2020 Feb; 128(2):126-132. PubMed ID: 31821740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homozygous deletions of methylthioadenosine phosphorylase in human biliary tract cancers.
    Karikari CA; Mullendore M; Eshleman JR; Argani P; Leoni LM; Chattopadhyay S; Hidalgo M; Maitra A
    Mol Cancer Ther; 2005 Dec; 4(12):1860-6. PubMed ID: 16373701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.